Dynavax Technologies Co. (NASDAQ:DVAX) Shares Purchased by HighVista Strategies LLC

HighVista Strategies LLC lifted its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 4.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 162,708 shares of the biopharmaceutical company’s stock after purchasing an additional 6,547 shares during the quarter. HighVista Strategies LLC owned about 0.12% of Dynavax Technologies worth $1,813,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in DVAX. GAMMA Investing LLC increased its holdings in shares of Dynavax Technologies by 175.5% in the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the last quarter. US Bancorp DE increased its holdings in shares of Dynavax Technologies by 291.4% in the third quarter. US Bancorp DE now owns 2,732 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 2,034 shares during the last quarter. Capital Performance Advisors LLP acquired a new stake in shares of Dynavax Technologies in the third quarter valued at approximately $45,000. Nisa Investment Advisors LLC increased its stake in Dynavax Technologies by 44.6% during the third quarter. Nisa Investment Advisors LLC now owns 5,441 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 1,679 shares during the last quarter. Finally, Centiva Capital LP purchased a new stake in Dynavax Technologies in the third quarter valued at $119,000. Institutional investors and hedge funds own 96.96% of the company’s stock.

Dynavax Technologies Price Performance

Shares of NASDAQ:DVAX opened at $13.04 on Tuesday. The company’s fifty day moving average price is $11.69 and its 200 day moving average price is $11.40. Dynavax Technologies Co. has a 12 month low of $9.74 and a 12 month high of $15.01. The company has a debt-to-equity ratio of 0.33, a current ratio of 13.23 and a quick ratio of 12.34. The firm has a market capitalization of $1.71 billion, a P/E ratio of 100.32 and a beta of 1.33.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. HC Wainwright restated a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a research report on Friday, November 8th. The Goldman Sachs Group decreased their price target on shares of Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating for the company in a research report on Thursday, August 8th.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.